Meropenem is a broad spectrum antibiotic that has been approved to treat other complicated intra-abdominal infections and complicated skin infections in older children and adults and for treating children under 3 months old for bacterial meningitis.
The approval came after NIH researchers performed a study to evaluate the dosing and safety of using the drug on infants who had complicated intra-abdominal infections. The study determined the antibiotic was safe to use in very young infants and was not associated with increased risk for serious side effects. The study also determined appropriate dosing.
More articles on antibiotics:
Diagnostic errors tied to overuse of antibiotics
Mystery of bacterial infection and heart complications solved
11 recent stories on antibiotics and drug resistance
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
